Biolase Technology, Inc.
<b>Corporate Headquarters</b>
4 Cromwell
Irvine
California
92618-1816
United States
Tel: 949-361-1200
Fax: 949-361-0204
Website: http://www.biolase.com/
Email: dentists@biolase.com
532 articles about Biolase Technology, Inc.
-
BIOLASE to Report Fourth Quarter and Full Year 2023 Results on March 21, 2024
3/14/2024
BIOLASE, Inc. announced that it will release fourth quarter and full year 2023 financial and operating results on Thursday, March 21, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.
-
Biolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in Dentistry
2/22/2024
BIOLASE, Inc., the globally recognized leader in dental laser technology, has launched its state-of-the-art all-tissue laser system, Waterlase iPlus Premier Edition™, and will be debuting it at the Chicago Midwinter Meeting 2024 from February 22nd to 24th at booth 4608.
-
BIOLASE, Inc. Announces Closing of $7.0 Million Public Offering
2/15/2024
BIOLASE, Inc., the global leader in dental lasers, announced the closing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock, one Class A Warrant to purchase one share of common stock, and one Class B Warrant to purchase one share of common stock.
-
BIOLASE, Inc. Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement
2/14/2024
BIOLASE, Inc. announced that it received notice from the Staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC that the Staff has determined to grant the Company an extension of time to regain compliance with Listing Rule 5550.
-
BIOLASE, Inc. Announces Pricing of $7.0 Million Public Offering
2/13/2024
BIOLASE, Inc. today announced the pricing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one Class A Warrant to purchase one share of common stock, and one Class B Warrant to purchase one share of common stock.
-
BIOLASE REPORTS UNAUDITED REVENUE GROWTH FOR FULL YEAR 2023 AND PROVIDES OUTLOOK FOR FULL YEAR 2024
1/29/2024
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced preliminary unaudited revenue results for 2023 based on currently available information and expects to report year-over-year growth as it continues to generate interest among dental practitioners for its industry leading lasers.
-
BIOLASE Successfully Concludes Waterlase iPlus All Tissue Laser Trial
12/12/2023
BIOLASE, Inc., the global leader in dental lasers, announced the successful completion of a trial program featuring the Waterlase iPlus All Tissue laser conducted by six leading U.S. dentists.
-
BIOLASE, Inc. Announces Pricing of $1.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
12/6/2023
BIOLASE, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.4 million of its common stock and pre-funded warrants in a registered direct offering and warrants to purchase common stock in a concurrent private placement, priced at-the-market under Nasdaq rules.
-
Biolase Reports Third Quarter Financial Results; Company Benefitting From Strategic Actions Taken to Streamline Operations and Gain Greater Operational Efficiencies
11/9/2023
BIOLASE, Inc., the global leader in dental lasers, announced its financial results for the third quarter ended September 30, 2023.
-
Landmark Study Performed by the Independent McGuire Institute Confirms Positive 12 Month Clinical Outcomes for BIOLASE REPAIR® Perio Protocol
11/8/2023
BIOLASE, Inc., the global leader in dental lasers, announced groundbreaking findings from a 12-month follow-up to a clinical trial performed at The McGuire Institute™.
-
Biolase to Report Third Quarter 2023 Results on November 9, 2023
11/7/2023
BIOLASE, Inc., the global leader in dental lasers, announced that it will release third quarter 2023 financial and operating results on Thursday, November 9, 2023, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.
-
BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
9/18/2023
BIOLASE, Inc. announced the closing of its previously announced underwritten public offering of 75,000 units, with each Unit consisting of one share of BIOLASE's Series J Convertible Redeemable Preferred Stock, par value $0.001 per share, with a liquidation preference of $100.00 per share, and one warrant to purchase one-half of one share of Series J Convertible Preferred Stock.
-
BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
9/14/2023
BIOLASE, Inc., a global leader in dental lasers, announced the pricing of an underwritten public offering of 75,000 units, with each Unit consisting of one share of BIOLASE's Series J Convertible Redeemable Preferred Stock, par value $0.001 per share, with a liquidation preference of $100.00 per share, and one warrant to purchase one-half of one share of Series J Convertible Preferred Stock.
-
Biolase Reports Record Consumable Sales as Total Second Quarter Revenue Increases 17% Year Over Year
8/10/2023
BIOLASE, Inc., the global leader in dental lasers, announced its financial results for the second quarter ended June 30, 2023.
-
Biolase to Report Second Quarter 2023 Results on August 10, 2023
8/2/2023
BIOLASE, Inc. announced that it will release second quarter 2023 financial and operating results on Thursday, August 10, 2023, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.
-
Biolase Announces 1-for-100 Reverse Stock Split
7/26/2023
BIOLASE, Inc., a global leader in dental lasers, announced that it held a special meeting of its stockholders on July 20, 2023 where the Company's stockholders granted the Board of Directors the discretion to effect a reverse stock split of the Company's common stock at a ratio between 1-to-2 and 1-to-100.
-
Biolase Epic Hygiene Dental Laser Receives Prestigious Cellerant Best of Class Hygiene Award
7/17/2023
BIOLASE, Inc., the global leader in dental lasers, announced that its Epic Hygiene dental laser, the only hygiene dental laser cleared by the U.S. Food and Drug Administration for laser bacterial reduction, has been awarded Cellerant's 2023 Best of Class Hygiene Award.
-
BIOLASE Announces Grand Opening of Training Facility to Reach Wider Universe of Dental Practitioners; First-Hand Experience Using Leading Dental Laser Technology Expected to Generate Increased Revenue Opportunities
6/15/2023
BIOLASE, Inc., the global leader in dental lasers, announced plans to open a state-of-the-art training facility, "BIOLASE Education Center" with an Open House scheduled for 5 PM Pacific time on Thursday, July 27, 2023.
-
Biolase to Participate in Maxim Group's 2023 Virtual Healthcare Conference Hosted by M-Vest on June 20th - 22nd
6/14/2023
BIOLASE, Inc., the global leader in dental lasers, announced that President and Chief Executive Officer, John Beaver and Chief Financial Officer, Jennifer Bright, have been invited to participate in the 2023 Virtual Healthcare Conference, presented by Maxim Group LLC and hosted by M-Vest, on June 20th to 22nd.
-
Biolase Announces Distribution of Series I Preferred Stock to Holders of Its Common Stock
6/5/2023
BIOLASE, Inc., a global leader in dental lasers, announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly-designated Series I Preferred Stock, par value $0.001 per share, for each outstanding share of BIOLASE common stock held of record as of 5:00 p.m. Eastern Time on June 16, 2023.